Manuel Espinoza, MD, PhD is a Professor of Public Health at Pontifical Catholic University of Chile and Honorary Fellow in the Centre for Health Economics at the University of York. Manuel leads the Unit of Health Technology Assessment at the Catholic University of Chile. He is the current President of the Chilean ISPOR Chapter and President elect of the ISPOR Latin America Consortium. He has served ISPOR as member of the ISPOR Latin America Consortium Executive Committee and member of the Latin America Conference Program Committee.
Manuel obtained his medical degree and a Master in Epidemiology, both from the Pontifical Catholic University of Chile. He also holds an MSc in Biostatistics from the University of Chile and an MSc and PhD in Health Economics, both from University of York. His work has been focused on the development of methods to explore heterogeneity in cost-effectiveness analysis as well as the incorporation of social value judgments in decision processes. He has also conducted applied research in cost-effectiveness analysis in areas such as cardiology, neurology, liver diseases, oncology and diabetes. Manuel has served as advisor for the Ministry of Health of Chile, the Institute of Public Health of Chile and several public entities in Latin America.
ISPOR Vision Statement by Manuel Espinoza, MD, MSc, PhD
Over the last decades, ISPOR has generated a fantastic scientific and international space that has been highly valued by the growing number of professionals being part of the organization. One thing that makes ISPOR special compared to other scientific societies is the vision of developing local and regional chapters. This policy has been responsible – at least in part – for the growth we have observed in regions such as Asia and Latin America. I believe ISPOR must keep this policy, strengthening the development of local chapters, improving access to information and encouraging the growth of the network at the regional level. The need for the knowledge and scientific innovation in pharmacoeconomics and outcomes research is not exclusive of high income countries. As an international entity, ISPOR has a social responsibility in the development of knowledge translation with an enhanced focus on low and middle income countries. I think ISPOR should maintain its efforts on improving its international outreach.
I would be very honored to be a part of the ISPOR Board of Directors. I think the society still needs to address the challenges of being a highly inclusive society but at the same time being capable of influencing and gathering public decision makers. This is a challenge at an international level but even more important at a regional level. My vision is that ISPOR uses its resources to support, help and positively influence the development of pharmacoeconomics and outcome research worldwide. However, this still needs our attention to make sure that the work we are doing is not only an academic exercise.